Cautious Hold Rating on GlaxoSmithKline Amid Strategic Acquisition and Financial Adjustments

TD Cowen analyst Steve Scala maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of $45.00.

Steve Scala has given his Hold rating due to a combination of factors surrounding GlaxoSmithKline’s recent strategic moves and financial projections. The acquisition of efimosfermin, a promising asset in the hepatology field, is seen as a strategic fit for GSK’s business development strategy, particularly in expanding their liver disease portfolio. This move aligns with the company’s focus on bolt-on deals and fibrosis, potentially offering R&D and commercial synergies with their existing pipeline.
However, while turnover estimates have been increased through 2030, there is a modest reduction in EPS projections for 2025-26, which may have contributed to the Hold rating. The financial commitment involved in the acquisition, including a substantial upfront payment and success-based milestones, also introduces a level of risk. These factors, combined with the long timeline for potential product launch, suggest a cautious approach, justifying the Hold rating.